• Explore /
  • Poster
  • / Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).

Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).

Abstract Video & Slides Poster

Authors

Sun Young Rha

Sun Young Rha

Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Sun Young Rha , Choong-Kun Lee , Hyo Song Kim , Beodeul Kang , Minkyu Jung , Woo Kyun Bae , Dong-Hoe Koo , Su-Jin Shin , Hei-Cheul Jeung , Dae Young Zang , Hyun Cheol Chung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immunobiology

Clinical Trial Registration Number

NCT02901301

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3081)

DOI

10.1200/JCO.2020.38.15_suppl.3081

Abstract #

3081

Poster Bd #

145

Abstract Disclosures

Similar Posters

First Author: Yelena Y. Janjigian

First Author: Joseph Chao

First Author: Charles S. Fuchs

First Author: Lin Shen